ASCO GI 2024 | KEYNOTE-811: HRQOL pembro plus tras and chemo in first-line HER2+ advanced gastric cancer

Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the Phase III KEYNOTE-811 (NCT03615326) trial, presenting key prespecified exploratory outcomes on health-related quality of life (HRQOL) in patients with untreated HER2+ metastatic gastric or gastroesophageal junction adenocarcinoma. The study compared first-line pembrolizumab (pembro) with trastuzumab and chemotherapy (pembrolizumab arm) against a placebo with trastuzumab and chemotherapy (pbo arm). Analysis of patient-reported outcomes (PRO) showed no negative impact on HRQOL with the addition of pembrolizumab. Completion rates were high, and similar changes in PRO scores were observed between the pembrolizumab and placebo arms. These findings, combined with safety and efficacy data, support the use of pembrolizumab with trastuzumab and chemotherapy as a first-line treatment for HER2+ advanced gastric cancer. This interview took place at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.